Posted 1 March 2021 PM
Health Minister Greg Hunt continued his drip-feed of March PBS listings today (Monday), adding to his weekend announcement on Sanofi's Dupixent for eczema, with news of first-time listings for BMS' Zeposia and Novartis' Atecture Breezhaler, plus an extension for Lilly's Trulicity.
"Thousands of Australians with multiple sclerosis, asthma and diabetes will benefit from the listing or extension of several medications on the Pharmaceutical Benefits Scheme (PBS), bringing further support to patients and their families," he said.